SCHEMBL10027311

SCHEMBL10027311

CCCc1cnc2c(O)c(C)ccn2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.36
▸ TP53 P04637 5/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ LMNA P02545 5/20 0.35
▸ CHEK1 O14757 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ DAPK3 O43293 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ PRKD3 O94806 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ PAK4 O96013 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ RET P07949 1/20 0.33
▸ IGF1R P08069 1/20 0.33
▸ MET P08581 1/20 0.33
▸ PDGFRB P09619 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19361118 0.87 AURKA (0.36) MAPTTP53HSD17B10LMNACHEK1
SCHEMBL24344138 0.85 HSD17B10 (0.36) MAPTTP53HSD17B10LMNAKDM4E
SCHEMBL10027189 0.85 LMNA (0.34) MAPTTP53HSD17B10LMNAAURKA
SCHEMBL10027291 0.85 MAPT (0.36) MAPTTP53HSD17B10LMNAAURKA
SCHEMBL17808748 0.82 LMNA (0.32) MAPTTP53LMNADHFR
SCHEMBL21577493 0.82 ALDH1A1 (0.35) MAPTHSD17B10LMNAKDM4EALDH1A1
SCHEMBL17802274 0.82 CHEK1 (0.51) MAPTTP53LMNACHEK1AURKA
SCHEMBL17808794 0.81 JAK2 (0.39) MAPTTP53LMNACHEK1AURKA
SCHEMBL17808764 0.81 PDE3B (0.36) FYNFLT1KDRKDM4E
SCHEMBL10027310 0.81 ALDH1A1 (0.35) MAPTTP53HSD17B10LMNACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO MAPT 38/4885TP53 3017/4885HSD17B10 2656/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO MAPT 38/4885TP53 3017/4885HSD17B10 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback